Literature DB >> 8177027

Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis.

B Strandvik1, R Hultcrantz.   

Abstract

Liver function tests and liver morphology were studied in 18 patients with cystic fibrosis (CF) for a period of 3 years. The patients were 5-19 years of age at the start of the study. Nine patients received regular supplementation of essential fatty acids (Intralipid) and nine sex- and age-matched patients, with as similar clinical status as possible but without fat emulsion treatment, were followed as controls. There were no significant differences between the two groups with regard to the parameters of liver function, including determinations of bile acids in serum and urine. Histological examinations of liver biopsies suggested less progression of liver disease in the fatty acid supplemented group, including fatty infiltration of the hepatocytes, evaluated morphometrically. The results show that regular supplementation of fat emulsions has no negative effects in the liver of patients with CF, and the lessening of progression of liver damage suggests that essential fatty acid deficiency might contribute to the liver damage in this disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8177027     DOI: 10.1111/j.1600-0676.1994.tb00004.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  4 in total

1.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

2.  Treatment of Gastrointestinal Problems in Cystic Fibrosis.

Authors:  Maria R. Mascarenhas
Journal:  Curr Treat Options Gastroenterol       Date:  2003-10

Review 3.  Nutrition in Cystic Fibrosis-Some Notes on the Fat Recommendations.

Authors:  Birgitta Strandvik
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

4.  Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.

Authors:  Fares Ayoub; Cesar Trillo-Alvarez; Giuseppe Morelli; Jorge Lascano
Journal:  World J Hepatol       Date:  2018-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.